ACRV
Acrivon Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.66
−5.68%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +9.8%
- EBIT
- +17.0%
- EPS
- +16.4%
- Free cash flow
- +12.4%
- Operating cash flow
- +11.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +77.4%
- EPS
- +12.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- +3.8%
- EBIT
- +5.7%
- Net income
- +3.3%
- EPS
- +3.8%
- Free cash flow
- +4.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026